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Background: The fruiting body of Ganoderma lucidum has been used as a traditional herbal medicine for many
years. However, to the date, there is no detailed study for describing the effect of G. lucidum spores on oxidative
stress, blood glucose level and lipid compositions in animal models of type 2 diabetic rats, in particular the effect
on the gene expression profiles associated with glucose and lipid metabolisms.
Methods: G. lucidum spores powder (GLSP) with a shell-broken rate >99.9 % was used. Adult male Sprague–Dawley
rats were randomly divided into three groups (n = 8/group). Group 1: Normal control, normal rats with ordinary
feed; Group 2: Model control, diabetic rats with ordinary feed without intervention; Group 3: GLSP, diabetic rats with
ordinary feed, an intervention group utilizing GLSP of 1 g per day by oral gavages for 4 consecutive weeks. Type 2
diabetic rats were obtained by streptozocin (STZ) injection. The changes in the levels of glucose, triglycerides, total
cholesterol and HDL-cholesterol in blood samples were analyzed after GLSP intervention. Meanwhile, gene expressions
associated with the possible molecular mechanism of GLSP regulation were also investigated using a quantitative
RT-PCR.
Results: The reduction of blood glucose level occurred within the first 2 weeks of GLSP intervention and the lipid
synthesis in the diabetic rats of GLSP group was significantly decreased at 4 weeks compared to the model control
group. Furthermore, it was also found that GLSP intervention greatly attenuated the level of oxidative stress in the
diabetic rats. Quantitative RT-PCR analysis showed up-regulation of lipid metabolism related genes (Acox1, ACC, Insig-1
and Insig-2) and glycogen synthesis related genes (GS2 and GYG1) in GLSP group compared to model control group.
Additionally, there were no significant changes in the expression of other genes, such as SREBP-1, Acly, Fas, Fads1, Gpam,
Dgat1, PEPCK and G6PC1.
Conclusion: This study might indicate that GLSP consumption could provide a beneficial effect in terms of lowering
the blood glucose levels by promoting glycogen synthesis and inhibiting gluconeogenesis. Meanwhile, GLSP treatment
was also associated with the improvement of blood lipid compositions through the regulation of cholesterol
homeostasis in the type 2 diabetic rats.
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Diabetes mellitus (DM) is a metabolic disorder caused
by a lack of insulin and/or pancreatic dysfunction char-
acterized by hyperglycemia. DM is a common, morbid
and costly disease, affecting more than 1 in 10 adults in
both United States and China [1]. DM is the leading
cause of new blindness, amputation and end-stage renal
diseases and it also contributes to a host of other condi-
tions. Although there is no published data for the
medical cost of diabetes in China in recent years, the
medical costs of managing DM and its complications
exceeded $115 billion in the United States alone in 2011
and the indirect costs added another $58 billion [1]. Evi-
dence suggests that DM complications can be markedly
attenuated with appropriate control of blood pressure
and hyperglycemia and with successful treatment of
hyperlipidemia. Thus, there is a great interest in novel
approaches to indirect DM management. However,
despite the increasing number of drugs available for DM
treatment, significant improvements in the control of
DM have not been observed [2].
Previous studies have confirmed that the treatment
with natural antioxidants can reduce diabetic complica-
tions [3] and the continuous efforts to discover new
antioxidants as useful drug candidates to combat dia-
betic complications are on-going. Ganoderma lucidum
(Leyss; Fr) Karst. (Ganodermataceae) is a well-known
Chinese traditional medicine which has been clinically
used in China, Japan and Korea for more than 2000 years.
Mushrooms of the genus Ganoderma have been shown
to be a rich source of biologically active metabolites [4],
containing many bioactive components, including triterpe-
noids, polysaccharides, nucleotides, sterols, steroids, pep-
tides and other bioactive ingredients [5]. G. lucidum spores
contain high levels of ganoderic acids, ergosterol peroxide
and pentadecanoate [6]. Many are active against current
major chronic diseases. For example, ganoderic acids, one
group of triterpenoids existing in the fruiting body of
G. lucidum showed anti-androgenic, anti-5 α-reductase,
anti-inflammatory and anti-tumor and a range of other
biological activities [7–9].
Although the fruiting body of G. lucidum has been
used as a traditional herbal medicine since ancient times,
the spores were utilized only in the late 20th century
[10]. The spores contain many bioactive substances, in-
cluding lanostane type triterpenes [11] and polysaccha-
rides [12] similar to those in the fruiting body [13].
Other characteristics of the bioactive compounds existing
in the spores are those they are also rich in fatty acids, in
particular long-chain C-19 fatty acids. Previous study
demonstrated that these fatty acids could inhibit tumor
cell proliferation and induce apoptosis in the HL-60, pro-
myelocytic leukemic cell line [14]. Meanwhile, other re-
search also showed the potential anti-hyperglycemic effectin diabetic rats using polysaccharides extracted from
G. lucidum fruiting body [15]. However, to the date, few
detailed studies described the effects of G. lucidum spores
on blood glucose and lipid compositions in streptozotocin
(STZ) induced diabetic rats and neither of the investiga-
tion of G. lucidum spores intervention on the gene expres-
sion of glucose and lipid metabolisms has been reported
in above diabetic model. To the best of our knowledge,
there are few reports in the literature evaluating the feasi-
bility of using G. lucidum spores as a potential anti-
diabetic agent and the descriptions of the molecular
mechanism(s) involved in these processes are also very
rare. Moreover, the co-existing of the multi-active com-
pounds in G. lucidum spores might provide a stronger
synergistic or positively effect on improving the diabetic
status than the consumption of the single active com-
pound. Therefore, in this study, STZ-induced-diabetic rats
are used to investigate the changes in the expression levels
of genes involved in lipid and glucose metabolisms after
G. lucidum spores treatment.
Results
Effect of GLSP intervention on the body mass of
diabetic rats
There was no significant difference in the initial weights
among the three groups (P = 0.6925) (Additional file 1:
Table S1), indicating that the random grouping was
acceptable. The body mass of the rats in the normal
control group gradually increased at 4 weeks, suggesting
that the dietary composition designed was appropriate.
After the injection of STZ, the rats in the two diabetic
groups (i.e. model control group and GLSP intervention
group) displayed a reduction of body mass gain and the
weight of the diabetic rats was lower than that of the
normal control group (P > 0.01) during the 4 consecutive
weeks, suggesting that the diabetic disease greatly af-
fected the normal development of these rats. There was
no significant difference in the body mass between the
model control and GLSP intervention group (P = 0.6099)
within the first 3 weeks. At the fourth week, the body
mass of GLSP group was higher by 9.0 % (P > 0.05) com-
pared to that of model group, indicating that GLSP con-
sumption could partially recover the weight loss after
4 weeks treatment.
Effect of GLSP intervention on blood glucose and insulin
levels in the diabetic rats
Following the injection of STZ, these animals displayed
the expected symptoms of insulin-dependent diabetes
mellitus, i.e. hyperglycemia, with glucose level around
30 mmol/L within 72 h of STZ injection. This symptom
remained relatively constant during the 4 subsequent
weeks. As shown in Table 1, GLSP intervention for 4
weeks led to a 21.0 % reduction of blood glucose level
Table 1 Effect of GLSP intervention on blood glucose level
Blood glucose level (mmol/L) RMANOVA F value P value
Group 72 h 1 week 2 week 3 week 4 week
Normal control 5.96 ± 0.64b 5.80 ± 0.83b 5.72 ± 0.29b 5.82 ± 0.79b 6.20 ± 0.52c 0.633 0.646
Model control 32.28 ± 1.00a 30.00 ± 3.32a 24.12 ± 6.60a 30.96 ± 3.04a 32.22 ± 1.71a 3.485 0.028
GLSP intervention 30.79 ± 2.72a 28.19 ± 8.32a 25.27 ± 3.98a 25.52 ± 7.48a 24.31 ± 1.17b 11.125 <0.001**
Results are expressed as means ± SD (n = 8, one-way ANOVA). Different superscript lowercase letters on the table indicate significant difference (P < 0.05). RMANOVA:
Repeated measures ANOVA. **Strongly significant (P value: P < 0.001). Normal control: healthy rats without intervention; Model control: STZ induced diabetic rats
without intervention; GLSP intervention: STZ induced diabetic rats with GLSP intervention
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the blood glucose level of the rats in GLSP group was
significantly lower than that of rats in model control
group (P < 0.05). Rats of GLSP intervention at 4 weeks
also exhibited a significant increase in the insulin level
compared to the rats of model control group (P < 0.05,
unpublished data).
Effect of GLSP intervention on blood lipid compositions
As shown in Table 2, diabetic rats in the model control
group had a significant higher in blood triglyceride (TG)
(P < 0.01) and total cholesterol (TC) (P < 0.01) compared
to the normal rats. Following the therapeutic treatment
of GLSP, the blood TG fell significantly by 49.0 % and
TC reduced by 17.8 %, respectively, as compared to the
non-treatment group (i.e. model control) (Table 2).
Although GLSP intervention did not attenuate the level
of TG and TC to a normal status, this study found that
G. lucidum intervention could significantly enhance the
level of high density lipoproteincholesterol (HDL-c) by
48.6 % (P < 0.01) compared to the model control. It is in-
teresting to note that there was no significant difference
in HDL-c between normal group and GLSP intervention
group (P = 0.6850).
Effect of GLSP intervention on oxidative stress level
High level of blood glucose for a long term could induce
mitochondrial reactive oxygen species (ROS). Thus, mal-
ondialdehyde (MDA) and ROS are the biomarkers com-
monly used for providing a reasonable index of oxidative
stress status. Diabetic disease significantly increased the
levels of oxidative stress (Table 3). For example, theTable 2 Effect of GLSP intervention on blood TG, TC and HDL-c
in diabetic rats
Group TG (mmol/L) TC (mmol/L) HDL-c (mmol/L)
Normal control 0.29 ± 0.00c 2.96 ± 0.07c 2.90 ± 0.07a
Model control 2.92 ± 0.27b 5.57 ± 0.47b 1.32 ± 0.45b
GLSP intervention 1.49 ± 0.55a 4.58 ± 0.09a 2.57 ± 0.29a
Results are expressed as means ± SD (n = 8, one-way ANOVA). Different
superscript lowercase letters on the table indicate significant difference (P< 0.05).
TG triglyceride, TC total cholesterol, HDL-c high density lipoprotein cholesterolblood MDA of diabetic rats without intervention (model
control) increased by 42.3 % (P < 0.01) compared to
normal ones and this was consistently accompanied by a
significant increase in ROS as well (Table 3).
As compared with the model control group, the MDA
level was 13.9 % lower at 4 weeks in the GLSP group
(Table 3) (P < 0.05). Furthermore, there was also a reduc-
tion of ROS for GLSP intervention group compared to
the model control, although the difference was not
significant. Nevertheless, the levels of glutathione perox-
idase (GSH-Px) and superoxide dismutase (SOD) were
higher by 25.9 % (P < 0.05) and 38.0 % (P < 0.05),
respectively, following the GLSP treatment compared to
the model control group.
Expression of genes related to glucose metabolism
In order to understand the molecular mechanism associ-
ated with the reduction of blood glucose level following
GLSP intervention, the expression of a number of genes
involved in glucose metabolism in the liver was analyzed
and the results are presented in Fig. 1. The analyses of
genes encoding enzymes involved in glycogen synthesis,
i.e. glycogen synthase2 (GS2) and glycogenin1 (GYG1)
showed that, compared to the model control group, the
expression level of hepatic GS2, the rate limiting enzyme
of glycogen synthesis, was increased by 3-folds and
GYG1 also had a more than 2-folds increase at 4 weeks
in the GLSP group. Furthermore, insulin-induced genes
(Insig-1 and Insig-2) were greatly up-regulated in the
livers of GLSP treated type 2 diabetic rats. More import-
antly, the expression level of isoform 1 of the catalytic
subunit of glucose-6-phosphatase (G6PC1) was found to
be greatly reduced after GLSP intervention, although
there was no significant difference in the expression
level of the genes related to gluconeogenesis, i.e., phos-
phenolpyruvate carboxykinase (PEPCK) between GLSP
intervention group and the model control group.
Expression of genes related to lipids metabolism
The pathways involved in lipid metabolism are various,
complexly inter-related to glucose and protein metabo-
lisms [16]. To assess the changes associated with the
control of lipogenesis, the expression level of gene
Table 3 Effect of GLSP intervention on the level of oxidative stress in diabetic rats
Group MDA (nmol/mL) ROS (U/mL) GSH-Px (U/mg prot.) SOD (U/mg prot.)
Normal control 6.49 ± 1.9a 53.96 ± 3.8a 1689.65 ± 220.1a 210.65 ± 7.7b
Model control 11.24 ± 0.2b 65.12 ± 7.6a 1223.26 ± 216.1b 179.26 ± 3.7c
GLSP intervention 9.68 ± 0.7a 61.12 ± 4.2a 1785.26 ± 259.7a 289.13 ± 4.0a
Results are expressed as means ± SD (n = 8, one-way ANOVA). Different superscript lowercase letters on the table indicate significant difference (P < 0.05). MDA
malondialdehyde, ROS reactive oxygen species, GSH-Px glutathione peroxidase, SOD superoxide dismutase
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and there was no significant difference in the expression
level among the three groups (Fig. 2). However, Acyl-CoA
oxidase1 (Acox1), which is involved in lipid β-oxidation,
was found to have the highest expression level in the
type 2 diabetic rats following the GLSP intervention
among the three groups. As described above, the ex-
pression levels of Insig-1 and Insig-2 were greatly up-
regulated in the liver of GLSP treated type 2 diabetic
rats compared to either normal rats or model control
rats. Once more, there were no significant differences
in the gene expression levels of Fads, SREBP-1, Acyl,
Gpam and Dgat1 between the model control group and
GLSP intervention group (Fig. 2).
Discussion
Although previous research has shown that the fruiting
bodies of G. lucidum could reduce blood glucose and
plasma cholesterol levels [17–19], few studies have
investigated the molecular mechanisms associated with
these activities. Our study combines the data of bio-
chemical analysis and gene expression and indicates thatFig. 1 Hepatic gene expression profiles for glucose metabolism. Mean valu
Model control: STZ induced diabetic rats without intervention; Normal con
with GLSP intervention. GS2 (glycogen synthase2, liver isoform) and GYG1 (gly
carboxykinase) and G6PC1 (isoform 1 of the catalytic subunit of glucose-6-pho
and Insig-2 (insulin induced gene 2): responsible for glucose homeostasisGLSP intervention could result in a partial recovery
of body weight, reduction of blood glucose level and im-
provement of lipid compositions and even attenuation of
oxidative stress in the STZ-induced diabetic rats. These
improvements might be highly associated with the
changes in the expression levels of the related genes.
The current study would suggest that GLSP interven-
tion could manipulate hyperglycemic and hyperlipidemic
status with a significant reduction of blood glucose level
and the improvement of blood lipid compositions (TG,
TC, HDL-c) in type 2 diabetic rats (P < 0.01). The GLSP
dosage used in this study was 1 g per day, which was
about 3 % of the total diet. Although this dosage did not
achieve a completely functional recovery of the DM rats
to a normal status, it could be used as a reference dosage
for improving the symptoms of DM. In contrast,
Winther et al. [20] reported that G. lucidum as mono-
therapy lowered C-peptide significantly (P < 0.001), leaving
HDL-c parameter unchanged.
As shown in Table 3, the level of oxidative stress in
diabetic rats was improved with the reduction of MDA
and the increase of SOD and GSH-Px following GLSPes with unlike letters are significantly different (one way ANOVA).
trol: healthy rats without intervention; GLSP:STZ induced diabetic rats
cogenin 1): related to glycogen synthesis; PEPCK (phosphenolpyruvate
sphatase): related to gluconeogenesis; Insig-1 (insulin induced gene 1)
Fig. 2 Hepatic gene expression profiles for lipid metabolism. Mean values with unlike letters are significantly different (one way ANOVA). ACC
(Acetyl-CoA carboxylse) and FAS (fatty acid synthase): related to lipogenesis; Gpam (glycerol-3-phosphate acyltransferase mitochondrial) and Dgat1
(diacylglycerol acyltransferase 1): responsible for triglycerides synthesis; Fads1 (fatty acid desaturase 1): associated with fatty acid desaturation;
Acox1 (acyl-CoA oxidase 1): responsible for fatty acid oxidation; Acly (ATP citrate lyase): related to cholesterol biosynthesis; Insig-1 (insulin induced
gene 1) and Insig-2 (insulin induced gene 2): regulation of cholesterol homeostasis; SREBP-1 (sterol regulatory element binding protein-1): associated
with the regulation of fatty acids and triglycerides syntheses and metabolism
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led to a reduction of ROS level compared to the model
control, although the difference was not significant.
Considering that MDA is produced from ROS, the
higher level of MDA may promote polyunsaturated fatty
acid peroxidation. Previous studies have also shown a
strong relationship between MDA levels and different
pathological stages of diabetes, because MDA concentra-
tion increased considerably in diabetes mellitus [21].
Thus, the controlling of MDA concentration would be
helpful in maintaining a suitable level of oxidative stress.
Antioxidant enzymes, including SOD and GSH-Px are
vital defenses against ROS and they are important in
inhibiting oxygen radical formation and usually act as
biomarkers for indicating ROS production. This study
found that the activities of antioxidant enzymes SOD
and GSH-Px were significantly decreased in the model
control group compared to the normal controls, indicat-
ing a lower antioxidant defense caused by diabetes.
However, the administration of GLSP significantly en-
hanced the activity of SOD and GSH-Px (Table 3), sug-
gesting that the antioxidant compounds present in GLSP
might enhance plasma antioxidant capacity in diabetic
rats. One plausible mechanism for interpreting the anti-
hyperglycemic function of GLSP might be through its
scavenging ability to protect pancreatic cells from
oxygen-radical damage, supporting an increased secre-
tion of insulin. Previous research has also demonstrated
that a high dosage of antioxidant compounds had a fa-
vorable effect on glucose homeostasis in obese subjectswith the improvements in their Homeostasis Model
Assessment (HOMA) index, thus exerting a positive
effect on insulin sensitivity [22].
Previous reports have shown the anti-hyperglycemic
activity of GLSP [17, 18] and this function was further
highlighted in this study (Table 1). A significant eleva-
tion of insulin levels in rats was also demonstrated after
the administration of GLSP (unpublished data), which
was also accompanied by a decreased blood glucose
level. The current study is consistent with previously
reported work [23]. Thus, the current results could fur-
ther support the evidence from previous studies on the
anti-hyperglycemic effect of GLSP through decreased
glucose level in animals accompanied with increased in-
sulin levels and improvements in pancreatic cell function
[24–27]. However, the mechanisms associated with this
benefit are not completely clear. Therefore, in light of
our current results, it might be hypothesized that the
benefits derived from GLSP intervention in the diabetic
rats could be partially associated with its roles in pro-
moting glycogen synthesis although gluconeogenesis was
not significantly affected (PECPK and G6PC1 in Fig. 1).
Another plausible reason may be associated with insulin
regulation. The expression level of insulin induced
genes, in particular Insig-1, was enhanced significantly in
GLSP intervention group compared to model control
group. It has been shown that Insig-1 and Insig-2 play an
important role in glucose homeostasis [28] and they also
have a key function in the regulation of intracellular
cholesterol and fat metabolism [29]. Consistently, previous
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could promote the expression levels of Insig-1 and Insig-2
genes [30] and Insig-1 inhibited lipid accumulation and free
fatty acid (FFA) synthesis in a time-dependent manner
[31]. In addition, the hepatic over-expression of Insig-1
(or Insig-2) would also inhibit the activation of SREBP-1c
in the rat liver [32–34], a key factor in the control of hep-
atic glucose metabolism and the manipulation of glucose
homeostasis associated with insulin. Although there was
no significant change in the expression level of SREBP-1
with the increased expression level of Insig genes in our
study, post transcriptional regulation might play some roles
as well.
In this study, the significant improvement of blood
lipid compositions confirmed that GLSP could be used
as an efficient therapy for treating hyperlipidemia caused
by diabetes and these improvements in blood cholesterol
and triglyceride levels might be related to the reduced
blood glucose level in the diabetic rats [35, 36]. Never-
theless, other study also suggested that G. lucidum con-
sumption could result in a great suppression of elevated
total cholesterol levels, which might be associated with
the inhibition of the hepatic phosphoenolpyruvate car-
boxykinase gene expression [17]. The HMG CoA reduc-
tase activity associated with lipoprotein metabolism may
also contribute to the hypolipidemic effects following
GLSP treatment, which is similar to the effects of other
plant medicines [37, 38]. Since Insig genes are also asso-
ciated with lipid metabolism, acyl-CoA oxidase plays an
important role in plasma lipid compositions. Fatty acid
degradation in most organisms occurs primarily via
β-oxidation. Both mitochondrial and peroxisomal β-
oxidation catalyze the shortening of acyl-CoA estersFig. 3 Gene regulation in metabolic pathways manipulated by GLSP in the
up-regulation or down-regulation, respectively. GLSP intervention reduced
GYG1) and glucose homeostasis (Insig-1 and Insig-2). Concomitantly, the red
might be associated with the increasing of genes expression of Acox1 andchains, which requires the participation of β-oxidation en-
zymes, including acyl-CoA dehydrogenase and acyl-CoA
oxidase (Acox) [39]. In our study, the Acox1 gene was
up-regulated by over 5-folds in the diabetic rats following
GLSP treatment, which might provide some clear evi-
dences that GLSP could reduce TG level mainly through
promoting lipid β-oxidation (Fig. 2). Thus, based on above
results in this study, a relationship between GLSP inter-
vention and the expression of genes involved in glucose
and lipid metabolisms in the diabetic rats is summarized
in Fig. 3. In brief, GLSP in the diet of type 2 diabetic rats
could reduce the blood glucose level possibly through the
increasing of the gene expression level of glycogen synthe-
sis (GS2 and GYG1) and glucose homeostasis (Insig-1 and
Insig-2). In particular, plasma lipid compositions (TG and
TC) decreased concomitantly with increased gene expres-
sion levels of Acox1 and Insig-1/2.
Conclusion
In summary, this study has shown that G. lucidum spores
could be used as an ingredient for attenuating diabetic
mellitus through potential anti-hyperglycemic and anti-
hyperlipidemic activities. More importantly, the relation-
ships between GLSP intervention and the changes in the
gene expression levels of the related glucose and lipid
metabolic pathways might highlight a potential model for
interpreting the action of GLSP treatment.
Materials and methods
Materials
G. lucidum spores powder (CLSP) with shell-broken
rate >99.9 % was provided by Chongqing Biotechnology
Institute (Chongqing, China).diet of type 2 diabetic rats. Arrows in red and green indicate gene
blood glucose level through increasing glycogen synthesis (GS2 and
uction of plasma lipids occurred following GLSP administration, which
Insig-1/2
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Twenty four healthy male Sprague–Dawley rats of ~200 g
weight were purchased from the Animal Resource
Centre, Medical College of PLA Military Science
(Beijing, China). They were housed in wire-bottomed
cages in a room with controlled temperature (23 °C)
and lighting (a 12-h-light/-darkcycle) and allowed free
access to food and water. The rats were randomly
assigned to 3 groups (n = 8/group): normal control,
model control and Ganoderma lucidum spores powder
(GLSP) treatment. The rats were fed with a basic diet.
After 1 week’s adaptive feeding with the basic diet, the
rats were fasted for 12 h, followed by a single intraven-
ous injection of 45 mg/ kgb.w STZ except the rats in
normal control group. After 72 h injection of STZ, the
blood glucose level was higher than 16.7 mmol/L dem-
onstrating a successful induction of diabetes. Normal
control and model control animals were fed with the
basal diet for 4 weeks without any intervention. In
contrast, GLSP was administered for the third group
by oral gavages, using a feeding needle with 1 g per
day for 4 consecutive weeks before they were sacri-
ficed for the analysis. There were no casualties or ob-
vious signs of toxicity throughout the course of the
experiments and all rats involved survived. The basal
diet contained 7 % fat and 13 % protein. Group food
intakes and individual body weights were monitored
daily throughout the study. Experimental procedures
were approved by the Animal Ethics Committee of
PLA Military Science and complied with the Chinese
Code of Practice for the Care and Use of Animals for
Scientific Purposes.Table 4 The primer of genes
Gene Accession number Forward primes(5′–3′) Reverse prim
18S rRNA NR_046237 AAACGGCTACCACATCCAAG TTGCCCTCCA
ACC NM_022193 CAACCACTACGGCATGACTCA CGCAGAAGC
FAS NM_017332 TGCTCCCAGCTGCAG GCCCGGTAG
Acox1 NM_017340 CAAGGAGAGTGCTACGGGTTA TTCAGGTAG
SREBP-1 XM_213329 GCAAGGCCATCGACTACATC TTTCATGCCC
Insig1 NM_022392 TTGTCGGCTTATTGTATCCCT GCACATTATT
Insig2 NM_178091 GGCGGAAGGAGAGACGGAGTC AAGCCAGGA
Acly NM_016987 GCAGACCAGAAGGGCGTGAC CACACTGCC
Fads1 NM_053445 GTTTGTGTGGGTGACGCAGAT TTGAAGGCT
Gpam NM_017274 CCTGTGGGCATCTCGTATGAT TTCCGCAGC
Dgat1 NM_053437 CAGATGGGGCTGCTGCTACAT GGCGGCACC
GS2 NM_013089 GACACTGAGCAGGGCTTTTCC GAGGAGGGC
GYG1 NM_031043.2 TCGCCAGCCCACAGGTT CACCACTGT
PEPCK NM_198780 GAAAGTTGAATGTGTGGGTGAT TTCTGGGTTG
G6PC1 NM_013098 GTATGGATTCCGGTGCTT AATGCCTGABiochemical analysis
During the whole experiment (4 weeks), blood samples
from all rats were collected from the tail vein (once a
week) for blood glucose level analysis. At the end of
the experiments, blood samples were collected from the
femoral artery before animals were sacrificed by cervical
dislocation. Blood collected was stored at −80 °C prior
to chemical analyses. High-density lipoprotein-cholesterol
(HDL-c) (North Kangtai Clinical Reagent Co., Beijing,
China, F003-2), total cholesterol (TC) (Dong’ou Diagnosis
Products Co Ltd, Zhejiang, China, F002-1) and triglyceride
(TG) (Dong’ou Diagnosis Products Co Ltd, Zhejiang,
China, F001-1) concentrations were measured according
to the instructions of their corresponding kits, respectively.
Plasma glutathione peroxidase (GSH-Px) (Jiancheng
Biological Engineering Institute, Nanjing, China, A061-1),
reactive oxygen species (ROS) (Sigma-Aldrich, USA,
DCFH-DA, D6883) and superoxide dismutase (SOD) were
measured by enzyme-linked immunosorbent assay (ELISA)
(Jiancheng Biological Engineering Institute, Nanjing, China,
A015). Commercially available ELISA kit was used to deter-
mine blood insulin levels (Beinglay Biotech Co., Ltd, Wuhan,
China, DRE20732).
Following the cervical dislocation, the rats were
dissected immediately with sterile scissors and the liver
was removed, weighed and immediately frozen in liquid
nitrogen and stored at −80 °C prior to RNA extraction.
Analysis of gene expression associated with lipid and
glucose metabolisms
Immediately after sacrifice, livers of all rats were quickly
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the Trizol reagent (Takara). Total RNA isolated from
liver was then treated with RNase-free DNase to re-
move any contaminating genomic DNA and the quality
and integrity of RNA were assessed using agarose gel
electrophoresis stained with ethidium bromide. For RT-
PCR analysis, first strand cDNA was synthesized using
the PrimeScript RT reagent kit with gDNA Eraser
(Takara) according to the manufacturer’s instructions.
PCR was carried out in a 20 μL volume reaction con-
taining 2 μM of each primer, 40 ng of cDNA and 10 μL of
SYBR Primix ExTag. Thermal cycling conditions included
an initial denaturation step at 95 °C for 5 min and then
40 cycles of 95 °C for 30 s, 58–60 °C for 30 s and 72 °C for
30 s. Fluorescence was measured at the end of each cycle.
The 18S rRNA gene was used as an internal control to
normalize target genes expression. Three replicates of
each reaction were performed and the relative transcript
quantity was calculated according to the method of 2-ΔΔCT
[40, 41]. Primer sequences are shown in Table 4.
Statistical analysis
Results were expressed as means ± SD with SPSS soft-
ware (version 13.0). The data were analyzed statistically
using one-way ANOVA, repeated measures ANOVA and
Tukey test (multiple comparisons). A value of P < 0.05 was
considered as statistically significant.
Additional file
Additional file 1: Table S1. Effect of GLSP intervention on body mass
of type 2 diabetic rats. Model control: STZ induced diabetic rats without
intervention; Normal control: healthy rats without intervention; GLSP:STZ
induced diabetic rats with GLSP intervention.
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